Compare GF & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GF | QSI |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.9M | 165.6M |
| IPO Year | N/A | 2020 |
| Metric | GF | QSI |
|---|---|---|
| Price | $10.79 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 22.4K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 28.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,436,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $618.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.98 | $0.69 |
| 52 Week High | $12.49 | $3.10 |
| Indicator | GF | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 40.41 |
| Support Level | $11.18 | $0.70 |
| Resistance Level | $11.82 | $0.79 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.70 | 3.04 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investments includes investments in different sectors such as the industrials, information technology, materials, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.